Neurotechnologies: How Geneva aims to compete with Silicon Valley

As artificial intelligence rapidly advances, the burgeoning field of neurotechnology, particularly brain implants, presents a critical question for Europe: can an industry demanding substantial capital, stringent regulation, and a long maturation period truly take root on the continent? Or will it, like so many other tech sectors, ultimately flourish elsewhere, leaving Europe behind? This is the challenge Geneva is confronting head-on.

“

une industrie aussi gourmande en capitaux, aussi réglementée et aussi lente à maturer peut-elle s’ancrer en Europe? Ou finira-t-elle, comme tant d’autres, par se développer ailleurs?

The Campus Biotech in Geneva has become a focal point for this ambition. A pivotal moment came in 2012 when Merck-Serono sold its Sécheron industrial site. Two billionaires, Ernesto Bertarelli, heir to the Serono family, and Hansjörg Wyss, founder of medical device pioneer Synthes, pooled their resources to acquire the complex for 300 million francs. Their vision was to transform it into a leading innovation hub, in collaboration with the EPFL.

Wyss further invested 100 million francs to establish the Wyss Center, a non-profit foundation designed to bridge the gap between academic neuroscience and industry. Its ambitious mission is to "enable the deaf to hear, the paralyzed to walk, and the blind to see." A decade later, this vision is beginning to materialize through advancements in neurosurgery, brain-computer interfaces, and neuromodulation therapies. A notable spin-off, Ability Neurotech, is poised to launch a brain implant that directly competes with Elon Musk's Neuralink, signaling tangible progress.

“

faire entendre les sourds, marcher les paralysés et voir les aveugles

This initiative builds on a strong foundation. Since the 1980s, Switzerland has fostered significant talent in neuroscience, creating a critical mass of expertise in French-speaking Switzerland. While international attention often fixates on Silicon Valley's dominance, Geneva's strategic investment and unique ecosystem, nurtured by philanthropic vision and academic excellence, position it as a serious contender. For us at Le Temps, this story is compelling because it highlights Europe's potential to carve out its own niche in cutting-edge technology, challenging the narrative that innovation is solely a U.S. or Asian prerogative. Geneva's effort demonstrates a commitment to developing neurotechnology with a focus on ethical considerations and patient well-being, distinct from the often breakneck pace seen elsewhere.

“

Dès les années 1980, le Fonds national a financé beaucoup de jeunes talents dans les neurosciences, rappelle le médecin et neuroscientifique Pierre Magistretti. Cela a permis de créer une masse critique en Suisse romande dans ce domaine.